Free tool
FAERS Monitor: Torisel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022088 or its brand name (Torisel, Temsirolimus). Reports on generic versions are filed under their own applications.
Reports
4,506
Serious
3,854
86% of reports
Hospitalization
2,003
Death reported
969
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- disease progression479
- death287
- dyspnoea216
- fatigue206
- pneumonia190
- diarrhoea189
- nausea189
- anaemia188
- pyrexia179
- vomiting176
- thrombocytopenia164
- dehydration162
- stomatitis156
- rash143
- renal cell carcinoma136
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 4 |
| 2007 | 132 |
| 2008 | 422 |
| 2009 | 352 |
| 2010 | 523 |
| 2011 | 426 |
| 2012 | 538 |
| 2013 | 399 |
| 2014 | 279 |
| 2015 | 328 |
| 2016 | 247 |
| 2017 | 153 |
| 2018 | 132 |
| 2019 | 119 |
| 2020 | 106 |
| 2021 | 79 |
| 2022 | 138 |
| 2023 | 60 |
| 2024 | 44 |
| 2025 | 16 |
| 2026 | 9 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,653 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| renal cell carcinomaSignal | 136 | 133.4 | 112.8 | 17,256 |
| disease progressionSignal | 479 | 19.0 | 17.4 | 8,148 |
| stomatitisSignal | 156 | 12.0 | 10.3 | 1,568 |
| thrombocytopeniaSignal | 164 | 6.9 | 5.9 | 817 |
| dehydrationSignal | 162 | 5.7 | 4.9 | 622 |
| anaemiaSignal | 188 | 4.6 | 4.0 | 531 |
| pneumoniaSignal | 190 | 2.7 | 2.4 | 211 |
| pyrexiaSignal | 179 | 2.4 | 2.1 | 149 |
| dyspnoea | 216 | 1.8 | 1.6 | 75 |
| vomiting | 176 | 1.7 | 1.5 | 57 |
| death | 287 | 1.6 | 1.4 | 59 |
| rash | 143 | 1.5 | 1.3 | 26 |
| diarrhoea | 189 | 1.4 | 1.2 | 19 |
| fatigue | 206 | 1.2 | 1.1 | 9 |
| nausea | 189 | 1.1 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.